Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Five9 Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.9 (market cap $4.59B), while Five9 Inc trades at $36.4 (market cap $2.63B). The key difference: Definium Therapeutics Inc. Common Shares is the larger of the two by market cap, and Five9 Inc is trading nearer its 52-week high, Definium Therapeutics Inc. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Five9 Inc for 72 Days on average.
| DFTX | FIVN | |
|---|---|---|
Market Cap | $4.59B | $2.63B |
Volume | 2,103,937 | 1,864,393 |
Sector | Health | Technology |
52-Week High | $48.45 | $38.65 |
52-Week Low | $10.68 | $13.61 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $3.55B | $2.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Five9 (FIVN) is trading at $35.15, up 4.06% with strong technical momentum and bullish moving average signals. The company shows accelerating revenue growth, reaching $1.15B in 2025 with improving profitability as net income turned positive at $39.42M. Recent quarterly earnings consistently beat expectations, while AI revenue surged 78% YoY to $39M in Q2 2026. The stock trades near resistance at $35 with solid institutional support despite recent insider selling activity.
FIVN presents growth potential driven by AI contact center adoption and subscription revenue expansion, but faces valuation concerns with a 51.69 P/E ratio. Key risks include competitive pressure in CCaaS markets and execution challenges in maintaining current growth trajectory. Analyst consensus remains bullish with 61% buy ratings and $34 price target, though current price exceeds consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
